Navigation Links
Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Date:2/14/2008

PRINCETON, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported unaudited financial results for the first fiscal quarter of 2008 ended December 31, 2007. Pharmasset reported a net loss attributable to common stockholders of $12.2 million, or ($0.57) per share for the first fiscal quarter of 2008, as compared to net income attributable to common stockholders of $3.6 million, or $0.33 per diluted share for the same period in fiscal 2007.

Revenues were $0.5 million during the first fiscal quarter of 2008, which consisted of the amortization of payments received from Roche from the hepatitis C virus (HCV) collaboration agreement that were previously recorded as deferred revenue. Revenues for the same period in fiscal 2007 were $8.1 million, which included a $7.5 million milestone payment received from Roche. Investment income was $0.9 million during the first fiscal quarter of 2008 compared to $0.4 million during the same period in 2007. The $0.5 million increase in the first fiscal quarter of 2008 was due to higher average invested cash balances.

Total costs and expenses for the first fiscal quarter of 2008 were $13.2 million as compared to $4.6 million for the same period in fiscal 2007. The $8.6 million increase in operating expenses for the first fiscal quarter of 2008 was primarily due to a $7.0 million increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B virus (HBV) infection, as well as approximately $1.6 million in drug discovery, compensation, insurance, audit and non-cash stock compensation expenses
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
2. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
3. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. CEL-SCI Corporation Reports First Quarter Financial Results
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
11. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HILL, N.C. , July 31, 2015  In ... of customers who are increasingly mobile, increasingly connected, and ... a growing variety of customer interaction channels and tools ... technology, including social media. According to ... the over the counter (OTC) segment in a call ...
(Date:7/31/2015)... , July 31, 2015 More than 1,500 ... country will convene in Indianapolis ... 2015 Mid-Year Training Institute . The week-long training, ... to address one of our nation,s biggest public health ... Mid-Year Training Institute is a one-of-a-kind intensive training opportunity, ...
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Pipeline Review, 2015 market research report that provides ... pipeline stage using data sourced from in-house databases, ... on syringes and needles market products pipeline spread ... organizations supported with 73 tables and 5 figures ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... to be presented at annual ICAAC/IDSA meeting in Washington, ... Corporation,have demonstrated for the first time in humans that ... speeds healing of,lesions as effectively as the leading oral ... new data provide the first proof of principle that ...
... Johnson Pharmaceutical,Research & Development, L.L.C. (J&JPRD), today ... doripenem for injection), a,carbapenem antibiotic, was found ... certain,strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases,(ESBLs) than ... a large group of bacteria that can ...
Cached Medicine Technology:Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5
(Date:8/1/2015)... ... August 01, 2015 , ... Have you ever wondered what “Karma” really means? Does it ... word “Karma.” , Vedic tradition, which gave birth to Hinduism, is one of the ... central concepts of this tradition. According to the wisdom of this heritage, Karma is a ...
(Date:8/1/2015)... ... , ... Brig and Lita Hart, icons of the network marketing industry and ... mission with the HOPE Movement of EvolvHealth. In what has been a long-term relationship ... to join their missions of purpose together to change the course of the network ...
(Date:8/1/2015)... ... 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair ... first small business donation to kick off the campaign for healing and Well-Being. , ... includes a complete line of raw, organic hair care products, as well as her ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable source of authentic tickets for ... Arena. Fans of every genre of music will have an act they are excited ... of the festival, the following artists will perform: Sam Smith, Coldplay, Kenny Chesney, The ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
Breaking Medicine News(10 mins):Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:March4thforWellBeing Foundation Kickoff 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2
... U.S. and Mexican-born Latinas seeking pregnancy and postpartum services ... levels of depression among the more "Americanized" women, report ... Health and The University of Texas Health Science Center ... of the Maternal and Child Health Journal. ...
... School of Medicine, Fox Chase Cancer Center and ... that will speed the translation of medical and ... , As part of the agreement, the ... Translational Medicine, based at Temple, to design and ...
... Position for Competing for Similar Projects in the Future, ... Continent and Strengthens its ... Technologies, jointly,owned (50:50) by The Israel Corporation Group subsidiary Israel ... desalination plant worth,over a 100 million Euros to a major ...
... JOLLA, Calif., Aug. 12 Duska Therapeutics,Inc. (OTC Bulletin ... from the U.S. Food and Drug Administration,s (the "FDA"),Division ... a proposed,Phase 3 clinical study with its lead drug, ... called paroxysmal,supraventricular tachycardia (PSVT)., On April 16, 2008, ...
... emotional distress to improve quality of life , , ... at increased risk for suicide, according to three new ... University of Washington analyzed U.S. data from 1973 to ... patients was 31.4 per 100,000 person-years, compared to 16.7 ...
... VIEW, Calif., Aug. 12 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ... 30, 2008., The net loss for the second quarter ... during the same period in 2007. The net,loss for the ... $15.3,million for the first six months of 2007. As of ...
Cached Medicine News:Health News:Public health clinic study links 'Americanization' and depression 2Health News:Public health clinic study links 'Americanization' and depression 3Health News:Temple, Fox Chase and Geisinger create Keystone Institute for Translational Medicine 2Health News:IDE Technologies Signs Contract Worth Over 100 Million Euros to Supply a Desalination Plant to Australia 2Health News:Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis 2Health News:Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis 3Health News:Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis 4Health News:Older Patients With Cancer at Heightened Suicide Risk 2Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 2Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 3Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 4Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 5Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: